Overview

Our strategy is to advance applications of TLR-targeted compounds through both internal development programs and through collaborative alliances. Our internal development programs are focused on drug candidates for the treatment of autoimmune and inflammatory diseases.

We are collaborating with Merck KGaA for the use of TLR9 agonists in cancer treatment, and Merck & Company for the development of TLR7, 8, and 9 agonists as vaccine adjuvants for cancer, infectious disease and Alzheimer’s disease.

We have additional programs in infectious diseases, respiratory diseases, hematologic oncology and additional vaccine adjuvant applications which we seek to advance through future collaborations.